Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026)
Avalo Therapeutics (AVTX) reported Other Non-Current Assets of $183000.0 for Q1 2026, up 39.69% on a YoY basis from $131000.0 in Q1 2025, and down 12.86% quarter-over-quarter from $210000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported Other Non-Current Assets for 13 years, with the latest figure at $183000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 39.69% year-over-year to $183000.0; the trailing twelve-month figure through Mar 2026 stood at $183000.0 (up 39.69% YoY), and the FY2025 full-year result was $210000.0, up 60.31% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $183000.0, down from $210000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $227000.0 in Q1 2022, with the low at $131000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $162235.3 across 5 years, with a median of $131000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 42.29% — and 2025, when it surged 60.31%.
- Avalo Therapeutics' Other Non-Current Assets stood at $131000.0 in 2022, then changed by 0.0% to $131000.0 in 2023, then changed by 0.0% to $131000.0 in 2024, then surged by 60.31% to $210000.0 in 2025, then retreated by 12.86% to $183000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $183000.0 (Q1 2026), $210000.0 (Q4 2025), and $210000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | 183,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183,000.00 |
| Dec 31, 2025 | 210,000.00 |
| Sep 30, 2025 | 210,000.00 |
| Jun 30, 2025 | 210,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 131,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 131,000.00 |
| Jun 30, 2023 | 131,000.00 |
| Mar 31, 2023 | 131,000.00 |
| Dec 31, 2022 | 131,000.00 |
| Sep 30, 2022 | 181,000.00 |
| Jun 30, 2022 | 227,000.00 |
| Mar 31, 2022 | 227,000.00 |
| Dec 31, 2021 | 227,000.00 |
| Sep 30, 2021 | 227,000.00 |
| Jun 30, 2021 | 149,000.00 |